Abstract：
Breast cancer is the most common malignancy and the second most common cause of cancer-related mortality in women. Triple-negative breast cancers do not express estrogen receptors, progesterone receptors, or human epidermal growth factor receptor 2 and have a higher recurrence rate, greater metastatic potential, and lower overall survival rate than those of other breast cancers. Treatment of triple-negative breast cancer is challenging; molecular-targeted therapies are largely ineffective and there is no standard treatment. In this review, we evaluate current attempts to classify triple-negative breast cancers based on their molecular features. We also describe promising treatment methods with different advantages and discuss genetic biomarkers and other prediction tools. Accurate molecular classification of triple-negative breast cancers is critical for patient risk categorization, treatment decisions, and surveillance. This review offers new ideas for more effective treatment of triple-negative breast cancer and identifies novel targets for drug development.
摘要：
乳腺癌是最常见的恶性肿瘤，也是女性癌症相关死亡的第二大常见原因。三阴性乳腺癌不表达雌激素受体，孕激素受体,或人类表皮生长因子受体2，具有较高的复发率，更大的转移潜力，总体生存率低于其他乳腺癌。三阴性乳腺癌的治疗具有挑战性；分子靶向治疗在很大程度上是无效的，并且没有标准的治疗方法。在这次审查中,我们根据三阴性乳腺癌的分子特征评估了目前对其进行分类的尝试.我们还描述了具有不同优势的有前途的治疗方法，并讨论了遗传生物标志物和其他预测工具。三阴性乳腺癌的准确分子分类对于患者风险分类至关重要。治疗决定，和监视。这篇综述为更有效地治疗三阴性乳腺癌提供了新思路，并确定了新的药物开发靶点。
